Long Hui-Deng, Ma Yu-Shui, Yang Hui-Qiong, Xue Shao-Bo, Liu Ji-Bin, Yu Fei, Lv Zhong-Wei, Li Ji-Yu, Xie Ru-Ting, Chang Zheng-Yan, Lu Gai-Xia, Xie Wen-Ting, Fu Da, Pang Li-Juan
Department of Pathology, Shihezi University School of Medicine, The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, 832003, Xinjiang, China.
Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
Mol Biol Rep. 2018 Dec;45(6):2615-2623. doi: 10.1007/s11033-018-4431-1. Epub 2018 Oct 19.
Hsa-MicroRNA-124a-3p (hsa-miR-124-3p) is involved in tumor progression in certain malignant tumors. However, its function and clinical implication in hepatocellular carcinoma (HCC) have not yet been illustrated. In this study, we explored the expression and prognostic value of hsa-miR-124-3p in patients with HCC. Hsa-miR-124-3p expression in HCC was analyzed in silico, which was subsequently confirmed by quantitative PCR in 155 HCC biopsy samples. Overall survival (OS) and disease-free survival in HCC patients was evaluated by Kaplan-Meier survival analysis, and univariate and multivariate Cox proportional hazard models were used. The in silico results demonstrated that hsa-miR-124-3p was reduced in cell lines and tissues of HCC, and hsa-miR-124-3p expression was lower in HCC tumor samples than in normal liver tissues. Moreover, a decrease in hsa-miR-124-3p expression was closely correlated with tumor diameter (≥ 5 cm) and number of lesions (multiple). Lower hsa-miR-124-3p expression was shown to be correlated with a shorter OS and poor prognosis in HCC. Our findings demonstrate that hsa-miR-124-3p might be a potential target for the diagnosis and prognosis of HCC.
人微小RNA-124a-3p（hsa-miR-124-3p）参与某些恶性肿瘤的肿瘤进展。然而，其在肝细胞癌（HCC）中的功能和临床意义尚未阐明。在本研究中，我们探讨了hsa-miR-124-3p在HCC患者中的表达及预后价值。通过计算机分析HCC中hsa-miR-124-3p的表达，随后在155例HCC活检样本中通过定量PCR进行验证。采用Kaplan-Meier生存分析评估HCC患者的总生存期（OS）和无病生存期，并使用单因素和多因素Cox比例风险模型。计算机分析结果表明，hsa-miR-124-3p在HCC细胞系和组织中表达降低，且HCC肿瘤样本中hsa-miR-124-3p的表达低于正常肝组织。此外，hsa-miR-124-3p表达降低与肿瘤直径（≥5 cm）和病灶数量（多个）密切相关。较低的hsa-miR-124-3p表达与HCC患者较短的OS和不良预后相关。我们的研究结果表明，hsa-miR-124-3p可能是HCC诊断和预后的潜在靶点。
